Stocktoria

Roivant Sciences Ltd. ROIV

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-12-03 · LEI

Roivant Sciences Ltd. statistics & valuation

Market cap$24.5B
P / B4.6×
Net margin-3629.2%
Return on equity-5.7%
FCF margin-9183.5%
Return on capital-9.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-3400.90% -1528.90% -3200.20% 13294.20% -592.00% -3629.20% 202120222023202420252026
Gross margin (%)
202120222023202420252026
Operating margin (%)
-4500.50% -2444.80% -2875.90% 13746.90% -3453.30% -6235.70% 202120222023202420252026
Return on equity (%)
-39.70% -41.50% -62.80% 67.40% -3.30% -5.70% 202120222023202420252026
Shares outstanding
651.6M 695.0M 760.1M 831.0M 725.4M 720.4M 202120222023202420252026
Net debt ($)
-$1.88B -$1.85B -$1.30B -$6.06B 202120222023202420252026
Share buybacks ($)
202120222023202420252026
Return on assets (%)
-31.20% -32.70% -42.20% 60.20% -3.20% -5.30% 202120222023202420252026
Free cash flow margin (%)
-2344.80% -1257.40% -2715.10% -2343.60% -2905.20% -9183.50% 202120222023202420252026
Debt / equity (×)
0.08× 0.10× 0.23× 0.07× 202120222023202420252026
EPS ($)
-$1.26 -$1.42 $5.23 -$0.24 -$0.54 202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021
Operating margin-6235.7%-3453.3%13746.9%-2875.9%-2444.8%-4500.5%
Net margin-3629.2%-592.0%13294.2%-3200.2%-1528.9%-3400.9%
FCF margin-9183.5%-2905.2%-2343.6%-2715.1%-1257.4%-2344.8%
Return on assets-5.3%-3.2%60.2%-42.2%-32.7%-31.2%
Return on equity-5.7%-3.3%67.4%-62.8%-41.5%-39.7%
Debt / equity——0.07×0.23×0.10×0.08×
Current ratio18.3733.4725.246.6011.649.99

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.